Program
flortaucipir
Also written as “Flortaucipir F18”, “[18F]Flortaucipir Injection” and “flortaucipir F 18”.
Its studies are mostly in Alzheimer Disease · Cognitive Dysfunction · Frontotemporal Dementia · Chronic Traumatic Encephalopathy · Supranuclear Palsy, Progressive, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 200 open or running | phase 3since Dec 16, 2013 | Nov 8, 2013 | none ahead |
| Eli Radiopharma | 11 open or running | phase 1since Apr 26, 2026 | Apr 26, 2026 | Dec 31, 2026phase 1 · NCT07580703 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Nov 8, 2013.
- Oct 28, 2014Phase 2 study in Alzheimer DiseaseEli Lilly · NCT02278367 · 179 enrolled · United States
- Oct 28, 2014Phase 1 study in Alzheimer DiseaseEli Lilly · NCT02278354 · 35 enrolled · United States
- Jan 8, 20152 phase 1 studies in Alzheimer DiseaseEli Lilly · NCT02350634, NCT02336360
- Jul 28, 2015Phase 1 study in Brain Injuries, TraumaticEli Lilly · NCT02512029 · United States
- Aug 3, 2015Phase 3 study in Alzheimer DiseaseEli Lilly · NCT02516046 · 156 enrolled · United States, Australia
- Jun 7, 2016Phase 2 study in Alzheimer DiseaseEli Lilly · NCT02795780 · 79 enrolled · United States
- Jan 31, 2017Phase 1 study in Frontotemporal DementiaEli Lilly · NCT03040713 · 16 enrolled · United States
- Feb 10, 2017Phase 1 study in Cognitive DysfunctionEli Lilly · NCT03052972 · 23 enrolled · United States
- Oct 16, 2017Phase 2 study in Alzheimer DiseaseEli Lilly · NCT03322462 · 155 enrolled · United States, Canada
- Mar 8, 2018Phase 2 study in Alzheimer DiseaseEli Lilly · NCT03467477 · 161 enrolled · United States
- Mar 27, 20192 phase 3 studies in Alzheimer DiseaseEli Lilly · NCT03901092, NCT03901105
- Jul 8, 2020Early phase 1 study in Alzheimer DiseaseEli Lilly · NCT04474405 · 36 enrolled · United States
- Jul 8, 2020Phase 1 study in Alzheimer DiseaseEli Lilly · NCT04468347 · 89 enrolled
- Apr 26, 2026Eli Radiopharma's first study: phase 1 study in Alzheimer DiseaseNew to Eli RadiopharmaEli Radiopharma · NCT07580703 · 18 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Alzheimer DiseaseEli Radiopharma · NCT07580703
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07580703Alzheimer Disease · China | 1 | Recruiting | Eli Radiopharma | Dec 31, 2026 | 18 |
| NCT04474405Alzheimer Disease · United States | Early 1 | Completed | Eli Lilly | Dec 9, 2013 | 36 |
| NCT04468347Alzheimer Disease | 1 | Completed | Eli Lilly | Feb 2018 | 89 |
| NCT03901105Alzheimer Disease · United States | 3 | Completed | Eli Lilly | Apr 28, 2019 | 205 |
| NCT03901092Alzheimer Disease · United States | 3 | Completed | Eli Lilly | Apr 26, 2019 | 242 |
| NCT03467477Alzheimer Disease · United States | 2 | Completed | Eli Lilly | Nov 15, 2018 | 161 |
| NCT03322462Alzheimer Disease · United States, Canada | 2 | Completed | Eli Lilly | Aug 31, 2018 | 155 |
| NCT03052972Cognitive Dysfunction · United States | 1 | Terminated | Eli Lilly | Aug 14, 2018 | 23 |
| NCT03040713Frontotemporal Dementia · United States | 1 | Completed | Eli Lilly | Oct 24, 2018 | 16 |
| NCT02795780Alzheimer Disease · United States | 2 | Completed | Eli Lilly | Aug 28, 2017 | 79 |
| NCT02516046Alzheimer Disease · United States, Australia | 3 | Completed | Eli Lilly | Jun 13, 2018 | 156 |
| NCT02512029Brain Injuries, Traumatic · United States | 1 | Withdrawn | Eli Lilly | Apr 2017 | 0 |
| NCT02350634Alzheimer Disease · United States | 1 | Completed | Eli Lilly | Jun 16, 2017 | 3 |
| NCT02336360Alzheimer Disease · United States | 1 | Completed | Eli Lilly | Jun 2015 | 6 |
| NCT02278367Alzheimer Disease · United States | 2 | Completed | Eli Lilly | Jun 26, 2019 | 179 |
| NCT02278354Alzheimer Disease · United States | 1 | Completed | Eli Lilly | Feb 3, 2017 | 35 |
| NCT02167594Supranuclear Palsy, Progressive · United States | 1 | Completed | Eli Lilly | Jul 11, 2016 | 29 |
| NCT02079766Chronic Traumatic Encephalopathy · United States | 2 | Completed | Eli Lilly | Oct 2015 | 41 |
| NCT02051764Alzheimer Disease · United States | 2 | Terminated | Eli Lilly | Dec 2016 | 44 |
| NCT02016560Alzheimer Disease · United States | 3 | Completed | Eli Lilly | Jul 28, 2017 | 383 |
| NCT01992380Alzheimer Disease · United States | 1 | Completed | Eli Lilly | May 30, 2014 | 24 |
How it is read
Names in the registry
- “Flortaucipir F18”, 17 entries
- “[18F]Flortaucipir Injection”, 1 entry
- “flortaucipir F 18”, 1 entry
- “flortaucipir F18”, 1 entry
- “18F-AV-1451”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 16 studies
- Cognitive Dysfunction, 1 study
- Frontotemporal Dementia, 1 study
- Chronic Traumatic Encephalopathy, 1 study
- Supranuclear Palsy, Progressive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.